Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/69798
IL-1β ENHANCES SUSCEPTIBILITY TO ATRIAL FIBRILLATION IN MICE BY ACTING THROUGH RESIDENT MACROPHAGES AND PROMOTING CASPASE-1 EXPRESSION
Author
Moreno-Loaiza, Oscar
Soares, Vinicius Cardoso
Souza, Manuela de Assumpção
Vera-Nuñez, Narendra
Guirao, Ainhoa Rodriguez de Yurre
Silva, Tatiana Pereira da
Pozes, Ana Beatriz
Perticarrari, Larissa
Monteiro, Evelin
Albino, Maria Clara
Silva, Sophia Barros
Dias, Suelen Silva Gomes
Maciel, Leonardo
Muzi-Filho, Humberto
Oliveira, Dahienne Ferreira de
Braga, Bruno Cabral
Diniz, Luan Pereira
Cruz, Mario Costa
Barbosa, Simone Reis
Castro-Junior, Archimedes Barbosa
Conde, Luciana
Cabral-Castro, Mauro Jorge
Souza, Olga Ferreira de
Pinheiro, Martha Valéria Tavares
Oliveira Junior, Nilson Araújo de
Siqueira, Leonardo Rezende de
Cosenza, Rodrigo Periquito
Fontoura, Claudio Munhoz da
Secco, Jose Carlos Pizzolante
Ferreira, Juliana da Rocha
Sousa, Andréa Silvestre de
Albuquerque, Denilson
Luiz, Ronir Raggio
Nicolau-Neto, Pedro
Pretti, Marco Antonio
Boroni, Mariana
Bonamino, Martin Hernán
Kasai-Brunswick, Tais Hanae
Mello, Debora Bastos
Gonçalves-Silva, Triciana
Peroba, Isalira
Bozza, Fernando Augusto
Madeiro, João Paulo do Vale
Pedrosa, Roberto Coury
Carneiro-Ramos, Marcela Sorelli
Martinho, Herculano da Silva
Bozza, Patrícia Torres
Souza, Fernanda Mesquita de
Silva, Gabriel Victor Lucena da
Cunha, Thiago M.
Uzelac, Ilija
Fenton, Flavio
Moll-Bernardes, Renata
Paiva, Claudia N.
Escobar, Ariel L.
Medei, Emiliano
Soares, Vinicius Cardoso
Souza, Manuela de Assumpção
Vera-Nuñez, Narendra
Guirao, Ainhoa Rodriguez de Yurre
Silva, Tatiana Pereira da
Pozes, Ana Beatriz
Perticarrari, Larissa
Monteiro, Evelin
Albino, Maria Clara
Silva, Sophia Barros
Dias, Suelen Silva Gomes
Maciel, Leonardo
Muzi-Filho, Humberto
Oliveira, Dahienne Ferreira de
Braga, Bruno Cabral
Diniz, Luan Pereira
Cruz, Mario Costa
Barbosa, Simone Reis
Castro-Junior, Archimedes Barbosa
Conde, Luciana
Cabral-Castro, Mauro Jorge
Souza, Olga Ferreira de
Pinheiro, Martha Valéria Tavares
Oliveira Junior, Nilson Araújo de
Siqueira, Leonardo Rezende de
Cosenza, Rodrigo Periquito
Fontoura, Claudio Munhoz da
Secco, Jose Carlos Pizzolante
Ferreira, Juliana da Rocha
Sousa, Andréa Silvestre de
Albuquerque, Denilson
Luiz, Ronir Raggio
Nicolau-Neto, Pedro
Pretti, Marco Antonio
Boroni, Mariana
Bonamino, Martin Hernán
Kasai-Brunswick, Tais Hanae
Mello, Debora Bastos
Gonçalves-Silva, Triciana
Peroba, Isalira
Bozza, Fernando Augusto
Madeiro, João Paulo do Vale
Pedrosa, Roberto Coury
Carneiro-Ramos, Marcela Sorelli
Martinho, Herculano da Silva
Bozza, Patrícia Torres
Souza, Fernanda Mesquita de
Silva, Gabriel Victor Lucena da
Cunha, Thiago M.
Uzelac, Ilija
Fenton, Flavio
Moll-Bernardes, Renata
Paiva, Claudia N.
Escobar, Ariel L.
Medei, Emiliano
Affilliation
Federal University of Rio de Janeiro. Institute of Biophysics Carlos Chagas Filho. Rio de Janeiro, RJ, Brazil / D'Or Institute for Research and Education. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Laboratory of Immunopharmacology. Rio de Janeiro, RJ, Brazil / Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Center for Research, Innovation and Surveillance in COVID-19 and Heath Emergencies. Rio de Janeiro, RJ, Brazil / Federal University of Rio de Janeiro. Program of Immunology and Inflammation. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biophysics Carlos Chagas Filho. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biophysics Carlos Chagas Filho. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biophysics Carlos Chagas Filho. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biophysics Carlos Chagas Filho. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biophysics Carlos Chagas Filho. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biophysics Carlos Chagas Filho. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biophysics Carlos Chagas Filho. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biophysics Carlos Chagas Filho. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biophysics Carlos Chagas Filho. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Laboratory of Immunopharmacology. Rio de Janeiro, RJ, Brazil / Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Center for Research, Innovation and Surveillance in COVID-19 and Heath Emergencies. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biophysics Carlos Chagas Filho. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biophysics Carlos Chagas Filho. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Medical Biochemistry Leopoldo de Meis. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biophysics Carlos Chagas Filho. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biomedical Sciences. Rio de Janeiro, RJ, Brazil.
Universidade de São Paulo. Centro de Facilidades e Apoio à Pesquisa. São Paulo, SP, Brasil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biophysics Carlos Chagas Filho. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biophysics Carlos Chagas Filho. Rio de Janeiro, RJ, Brazil.
Universidade Federal do Rio de Janeiro. Instituto de Microbiologia Paulo de Góes. Rio de Janeiro, RJ, Brasil / Fluminense Federal University. Pathology Department. Niterói, RJ, Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ, Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ, Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ, Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ, Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ, Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ, Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ, Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ, Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ, Brazil.
Rio de Janeiro State University. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute for Studies in Public Health. Rio de Janeiro, RJ, Brazil / Federal University of Rio de Janeiro. Clementino Fraga University Hospital. Rio de Janeiro, RJ, Brazil.
Brazilian National Cancer Institute. Research Coordination. Molecular Carcinogenesis Program. Rio de Janeiro, RJ, Brazil.
National Cancer Institute. Research Coordination. Cell and Gene Therapy Program. Rio de Janeiro, RJ, Brazil.
Brazilian National Cancer Institute. Division of Experimental and Translational Research. Laboratory of Bioinformatics and Computational Biology. Rio de Janeiro, RJ, Brazil.
Brazilian National Cancer Institute. Research Coordination. Molecular Carcinogenesis Program. Rio de Janeiro, RJ, Brazil / Oswaldo Cruz Foundation. Vice-Presidency of Research and Biological Collections. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biophysics Carlos Chagas Filho. Rio de Janeiro, RJ, Brazil / Federal University of Rio de Janeiro. National Center for Structural Biology and Bioimaging. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. National Center for Structural Biology and Bioimaging. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. National Center for Structural Biology and Bioimaging. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. National Center for Structural Biology and Bioimaging. Rio de Janeiro, RJ, Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ, Brazil / Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em Medicina Intensiva. Rio de Janeiro, RJ, Brasil.
Federal University of Ceará. Department of Computing Science. Fortaleza, CE, Brazil.
Federal University of Rio de Janeiro. Clementino Fraga University Hospital. Rio de Janeiro, RJ, Brazil.
Federal University of ABC. Center for Natural and Human Sciences. Santo André, SP, Brazil.
Federal University of ABC. Center for Natural and Human Sciences. Santo André, SP, Brazil.
Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Laboratory of Immunopharmacology. Rio de Janeiro, RJ, Brazil / Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Center for Research, Innovation and Surveillance in COVID-19 and Heath Emergencies. Rio de Janeiro, RJ, Brazil.
University of Sao Paulo. Ribeirão Preto Medical School. Center of Research in Inflammatory Diseases. Ribeirao Preto, SP, Brazil / University of Sao Paulo. Ribeirao Preto Medical School. Department of Pharmacology. Ribeirao Preto, SP, Brazil.
Federal University of ABC. Center for Natural and Human Sciences. Santo André, SP, Brazil / University of Sao Paulo. Ribeirão Preto Medical School. Center of Research in Inflammatory Diseases. Ribeirao Preto, SP, Brazil.
University of Sao Paulo. Ribeirão Preto Medical School. Center of Research in Inflammatory Diseases. Ribeirao Preto, SP, Brazil / University of Sao Paulo. Ribeirao Preto Medical School. Department of Pharmacology. Ribeirao Preto, SP, Brazil.
Virginia Commonwealth University. Richmond, VA, USA.
School of Physics. Georgia Tech. Atlanta, GA, USA.
D'Or Institute for Research and Education. Rio de Janeiro, RJ, Brazil.
Universidade Federal do Rio de Janeiro. Instituto de Microbiologia Paulo de Góes. Rio de Janeiro, RJ, Brasil.
University of California. School of Engineering. Department of Bioengineering. Merced, CA, USA.
Federal University of Rio de Janeiro. Institute of Biophysics Carlos Chagas Filho. Rio de Janeiro, RJ, Brazil / D'Or Institute for Research and Education. Rio de Janeiro, RJ, Brazil / Federal University of Rio de Janeiro. National Center for Structural Biology and Bioimaging. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Laboratory of Immunopharmacology. Rio de Janeiro, RJ, Brazil / Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Center for Research, Innovation and Surveillance in COVID-19 and Heath Emergencies. Rio de Janeiro, RJ, Brazil / Federal University of Rio de Janeiro. Program of Immunology and Inflammation. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biophysics Carlos Chagas Filho. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biophysics Carlos Chagas Filho. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biophysics Carlos Chagas Filho. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biophysics Carlos Chagas Filho. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biophysics Carlos Chagas Filho. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biophysics Carlos Chagas Filho. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biophysics Carlos Chagas Filho. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biophysics Carlos Chagas Filho. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biophysics Carlos Chagas Filho. Rio de Janeiro, RJ, Brazil.
Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Laboratory of Immunopharmacology. Rio de Janeiro, RJ, Brazil / Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Center for Research, Innovation and Surveillance in COVID-19 and Heath Emergencies. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biophysics Carlos Chagas Filho. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biophysics Carlos Chagas Filho. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Medical Biochemistry Leopoldo de Meis. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biophysics Carlos Chagas Filho. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biomedical Sciences. Rio de Janeiro, RJ, Brazil.
Universidade de São Paulo. Centro de Facilidades e Apoio à Pesquisa. São Paulo, SP, Brasil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biophysics Carlos Chagas Filho. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biophysics Carlos Chagas Filho. Rio de Janeiro, RJ, Brazil.
Universidade Federal do Rio de Janeiro. Instituto de Microbiologia Paulo de Góes. Rio de Janeiro, RJ, Brasil / Fluminense Federal University. Pathology Department. Niterói, RJ, Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ, Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ, Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ, Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ, Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ, Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ, Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ, Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ, Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ, Brazil.
Rio de Janeiro State University. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute for Studies in Public Health. Rio de Janeiro, RJ, Brazil / Federal University of Rio de Janeiro. Clementino Fraga University Hospital. Rio de Janeiro, RJ, Brazil.
Brazilian National Cancer Institute. Research Coordination. Molecular Carcinogenesis Program. Rio de Janeiro, RJ, Brazil.
National Cancer Institute. Research Coordination. Cell and Gene Therapy Program. Rio de Janeiro, RJ, Brazil.
Brazilian National Cancer Institute. Division of Experimental and Translational Research. Laboratory of Bioinformatics and Computational Biology. Rio de Janeiro, RJ, Brazil.
Brazilian National Cancer Institute. Research Coordination. Molecular Carcinogenesis Program. Rio de Janeiro, RJ, Brazil / Oswaldo Cruz Foundation. Vice-Presidency of Research and Biological Collections. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. Institute of Biophysics Carlos Chagas Filho. Rio de Janeiro, RJ, Brazil / Federal University of Rio de Janeiro. National Center for Structural Biology and Bioimaging. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. National Center for Structural Biology and Bioimaging. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. National Center for Structural Biology and Bioimaging. Rio de Janeiro, RJ, Brazil.
Federal University of Rio de Janeiro. National Center for Structural Biology and Bioimaging. Rio de Janeiro, RJ, Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ, Brazil / Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em Medicina Intensiva. Rio de Janeiro, RJ, Brasil.
Federal University of Ceará. Department of Computing Science. Fortaleza, CE, Brazil.
Federal University of Rio de Janeiro. Clementino Fraga University Hospital. Rio de Janeiro, RJ, Brazil.
Federal University of ABC. Center for Natural and Human Sciences. Santo André, SP, Brazil.
Federal University of ABC. Center for Natural and Human Sciences. Santo André, SP, Brazil.
Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Laboratory of Immunopharmacology. Rio de Janeiro, RJ, Brazil / Oswaldo Cruz Foundation. Oswaldo Cruz Institute. Center for Research, Innovation and Surveillance in COVID-19 and Heath Emergencies. Rio de Janeiro, RJ, Brazil.
University of Sao Paulo. Ribeirão Preto Medical School. Center of Research in Inflammatory Diseases. Ribeirao Preto, SP, Brazil / University of Sao Paulo. Ribeirao Preto Medical School. Department of Pharmacology. Ribeirao Preto, SP, Brazil.
Federal University of ABC. Center for Natural and Human Sciences. Santo André, SP, Brazil / University of Sao Paulo. Ribeirão Preto Medical School. Center of Research in Inflammatory Diseases. Ribeirao Preto, SP, Brazil.
University of Sao Paulo. Ribeirão Preto Medical School. Center of Research in Inflammatory Diseases. Ribeirao Preto, SP, Brazil / University of Sao Paulo. Ribeirao Preto Medical School. Department of Pharmacology. Ribeirao Preto, SP, Brazil.
Virginia Commonwealth University. Richmond, VA, USA.
School of Physics. Georgia Tech. Atlanta, GA, USA.
D'Or Institute for Research and Education. Rio de Janeiro, RJ, Brazil.
Universidade Federal do Rio de Janeiro. Instituto de Microbiologia Paulo de Góes. Rio de Janeiro, RJ, Brasil.
University of California. School of Engineering. Department of Bioengineering. Merced, CA, USA.
Federal University of Rio de Janeiro. Institute of Biophysics Carlos Chagas Filho. Rio de Janeiro, RJ, Brazil / D'Or Institute for Research and Education. Rio de Janeiro, RJ, Brazil / Federal University of Rio de Janeiro. National Center for Structural Biology and Bioimaging. Rio de Janeiro, RJ, Brazil.
Abstract
Atrial fibrillation (AF) is more prevalent in patients with elevated interleukin (IL)-1β levels. Here we show that daily administration of IL-1β for 15 days sensitizes mice to AF, leading to fibrosis, accumulation of β-pleated sheet proteins in the left atrium, and systemic inflammation, resembling the pathophysiological changes observed in patients with AF. IL-1β administration creates a positive feedback loop, dependent on the IL-1 receptor (IL-1R) activity in cardiac resident macrophages. This results in increased caspase-1 maturation in the left atrium and elevated Il1b and Casp1 transcription in atrial macrophages. IL-1β treatment accelerated action potential and Ca2+ restitution in the left atrium, leading to action-potential shortening. This, along with increased caspase-1 maturation and IL-1R signaling, was essential for inducing AF. Lack of IL-1R in macrophages, but not cardiomyocytes, prevented IL-1β-induced AF sensitivity. By depleting recruited macrophages or deleting IL-1R specifically in cardiac resident macrophages, we further demonstrate that IL-1β/IL-1R signaling in these resident macrophages is responsible for increased AF susceptibility. These findings offer insights into the therapeutic potential of targeting IL-1β/IL-1R signaling in patients with AF and emphasize the importance of recognizing different underlying causes in this patient group.
Publisher
Springer Nature
Citation
MORENO-LOAIZA, Oscar et al. IL-1β enhances susceptibility to atrial fibrillation in mice by acting through resident macrophages and promoting caspase-1 expression. Nature Cardiovascular Research, v. 4, n. 3, p. 1-50, Mar. 2025.DOI
10.1038/s44161-025-00610-8ISSN
2731-0590Related items
Showing items related by title, author, creator and subject.
-
Recomendações e orientações em saúde mental e atenção psicossocial na COVID-19
Pizzinato, Adolfo et al. | Date Issued: 2020No mesmo ano de celebração de seus 120 anos, a Fundação Oswaldo Cruz vem mobilizando toda a sua experiência, infraestrutura, recursos e conhecimentos para o enfrentamento de uma das maiores crises sanitárias desde a pandemia ... -
Covid-19 no Brasil: cenários epidemiológicos e vigilância em saúde
Caldas, Aline Diniz Rodrigues et al. | Date Issued: 2021Apresentar um diagnóstico e constituir uma memória sobre a evolução da pandemia no Brasil, a partir de registros e análises de dados, sistemas de monitoramento e vigilância em saúde. É com esse intuito que o Observatório ... -
Manual de tecnovigilância: uma abordagem sob ótica da vigilância sanitária
Santos, Ana Clara Ribeiro Bello dos et al. | Date Issued: 2021O Manual valoriza aspectos históricos da vigilância sanitária e da tecnovigilância no Brasil e no mundo e descreve práticas adotadas na atualidade. Também destaca algumas tecnologias que, apesar de consolidadas, se ...
Share